Advancing More Equitable Care Through the Development of a Health Equity Report Card
The root causes of racial disparities in access to optimal cancer care and related cancer outcomes are complex, multifactorial, and not rooted in biology. Contributing factors to racial disparities in care delivery include implicit and explicit bias, lack of representation of people of color in the oncology care and research workforce, and homogenous research participants that are not representative of the larger community. Systemic and structural barriers include policies leading to lack of insurance and underinsurance, costs of cancer treatment and associated ancillary costs of care, disparate access to clinical trials, and social determinants of health, including exposure to environmental hazards, access to housing, childcare, and economic injustices. To address these issues, ACS CAN, NCCN, and NMQF convened the Elevating Cancer Equity (ECE) initiative. The ECE Working Group developed the Health Equity Report Card (HERC). In this manuscript, we describe the process taken by the ECE Working Group to develop the HERC recommendations, the strategies employed by NCCN to develop an implementation plan and scoring methodology for the HERC, and next steps to pilot the HERC tool in practice settings.
Submitted November 3, 2022; final revision received January 5, 2023; accepted for publication January 6, 2023.
Disclosures: The authors have disclosed that they have no financial interests, arrangements, or affiliations with the manufacturers of any products discussed in this article or their competitors. A. Schatz, C.D. Denlinger, L. Bandini, and R.W. Carlson are employed by NCCN.
Funding: The ECE Working Group was funded by 2seventy bio (formally known as Bluebird); AbbVie; Bristol Myers Squibb; Genentech; GlaxoSmithKline; Janssen; Lilly; Merck & Co., Inc.; MorphoSys; Pfizer Oncology; Regeneron; Sanofi; and Taiho Oncology.
Supplementary Materials
- Supplemental Materials (PDF 528 KB)
© 2019-2023 National Comprehensive Cancer Network